Phathom pharmaceuticals reports first quarter 2025 financial results and provides business update

Voquezna launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers net revenues of $28.5 million reported for q1 filled voquezna prescriptions increased ~8% in q1 over the prior quarter despite seasonal headwinds strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 management to host conference call today, may 1, 2025, at 8:00 a.m. et florham park, n.j.
ITCI Ratings Summary
ITCI Quant Ranking